By otakuyassine3@gmail.com 
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are stocks of companies that specialize in biotechnology, which involves using biological systems and living organisms to develop products and technologies for various industries such as healthcare, agriculture, and environmental science. These stocks can be highly volatile due to the unpredictable nature of drug development and regulatory approvals, offering potential for high returns but also significant risks. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE ABBV traded up $8.25 during mid-day trading on Friday, reaching $183.90. 11,926,469 shares of the company’s stock were exchanged, compared to its average volume of 5,362,292. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The business has a fifty day simple moving average of $176.57 and a 200 day simple moving average of $184.95. AbbVie has a twelve month low of $153.58 and a twelve month high of $207.32. The firm has a market capitalization of $324.98 billion, a price-to-earnings ratio of 63.85, a PEG ratio of 1.77 and a beta of 0.58.
Read Our Latest Research Report on ABBV
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ:VRTX traded up $23.28 during midday trading on Friday, reaching $461.68. 3,646,769 shares of the company were exchanged, compared to its average volume of 1,346,207. The firm has a market cap of $118.90 billion, a PE ratio of -232.00, a P/E/G ratio of 2.29 and a beta of 0.40. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The stock has a fifty day simple moving average of $434.55 and a two-hundred day simple moving average of $463.11. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.
Read Our Latest Research Report on VRTX
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of Thermo Fisher Scientific stock traded down $8.34 during trading on Friday, reaching $598.40. The stock had a trading volume of 2,165,717 shares, compared to its average volume of 1,840,120. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $228.89 billion, a price-to-earnings ratio of 37.52, a P/E/G ratio of 3.89 and a beta of 0.76. Thermo Fisher Scientific has a 52 week low of $493.30 and a 52 week high of $627.88. The stock has a fifty day moving average price of $541.37 and a two-hundred day moving average price of $570.96.
Read Our Latest Research Report on TMO
Featured Stories